leadf
logo-loader
viewSourceBio International plc

SourceBio International shares defy the gloom to move to a premium on their AIM debut

At 9am the stock was up 11p at 173p, providing those who backed the float with a modest early profit on their investment

xxxxx

Lab services specialist SourceBio International plc (LON:SBI) defied the early gloom to get off to a premium start on its first day of trading on AIM.

At 9 am the stock was up 11p at 173p, providing those who backed the float with a modest early profit on their investment.

For the business, the £35mln raised will be used to scale up COVID-19 testing capacity as well as paying off shareholder and bank loans.

The positive debut has added around £8mln to SourceBio’s initial £120mln market capitalisation.

Chairman Jay LeCoque said: "We are delighted by the strong support we've received from new institutional investors and our existing shareholders.

“Our IPO on AIM allows us to significantly increase our COVID-19 testing capacity, accelerate earnings growth in our core business and execute on potential M&A opportunities.

“It's an exciting time for our business and we look forward to executing on our ambitious growth plans and delivering value to our shareholders."

Quick facts: SourceBio International plc

Price: 177 GBX

AIM:SBI
Market: AIM
Market Cap: £131.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SourceBio International plc named herein, including the promotion by the Company of SourceBio International plc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

SourceBio International gets set for IPO as Covid-19 testing demand becomes...

SourceBio International's (LON:SBI) Jay LeCoque talks to Proactive London's Katie Pilbeam ahead of their IPO on AIM. He explains that Covid-19 is now their main focus, to support the government effort to get the pandemic testing campaign under control. The IPO, values the company at £120m,...

on 28/10/20

2 min read